According to Compugen's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.33184. At the end of 2023 the company had a P/S ratio of 5.23.
Year | P/S ratio | Change |
---|---|---|
2023 | 5.23 | -36.87% |
2022 | 8.28 | -86.15% |
2021 | 59.8 | -88.06% |
2020 | 501 | |
2019 | N/A | -100% |
2018 | 7.56 | |
2017 | N/A | -100% |
2016 | 366 | 972.79% |
2015 | 34.1 | 0.48% |
2014 | 34.0 | -66.33% |
2013 | 101 | -86.52% |
2012 | 749 | |
2011 | N/A | -100% |
2010 | 171 | -73.26% |
2009 | 638 | 1657.87% |
2008 | 36.3 | -84.39% |
2007 | 232 | -1.23% |
2006 | 235 | 467.05% |
2005 | 41.5 | 17.02% |
2004 | 35.5 | 130.82% |
2003 | 15.4 | 266.99% |
2002 | 4.19 | -61.18% |
2001 | 10.8 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Seagen
SGEN | 18.8 | 251.85% | ๐บ๐ธ USA |
Genetic Technologies GENE | 0.3520 | -93.40% | ๐ฆ๐บ Australia |
Teva Pharmaceutical Industries TEVA | 1.20 | -77.43% | ๐ฎ๐ฑ Israel |
Eterna Therapeutics ERNA | 102 | 1,815.96% | ๐บ๐ธ USA |